Assignee
IDEAYA BIOSCIENCES INC
US·13 granted patents·26 pending applications·14 citations·filing 2018–2025
Top patents by PatentIndex Score
39 records- 0193US11084798B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Aug 10, 2021·3 cites·26 claims
- 0291US12269820B2Piperazine substituted indazole compounds as inhibitors of PARGIDEAYA BIOSCIENCES INC·Filed 2023·Granted Apr 8, 2025·1 cites·12 claims
- 0390US11130759B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Sep 28, 2021·2 cites·26 claims
- 0490US11046691B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Jun 29, 2021·2 cites·28 claims
- 0587US10815250B2AhR modulatorsIDEAYA BIOSCIENCES INC·Filed 2019·Granted Oct 27, 2020·3 cites·24 claims
- 0684US12115163B2Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitorIDEAYA BIOSCIENCES INC·Filed 2024·Granted Oct 15, 2024·1 cites·17 claims
- 0784US11407764B2AhR modulatorsIDEAYA BIOSCIENCES INC·Filed 2020·Granted Aug 9, 2022·1 cites·19 claims
- 0875US11584755B2Dihydrothieno[3,2-b]pyridine compoundsIDEAYA BIOSCIENCES INC·Filed 2018·Granted Feb 21, 2023·1 cites·18 claims
- 0974US12258354B2AhR modulatorsIDEAYA BIOSCIENCES INC·Filed 2022·Granted Mar 25, 2025·0 cites·14 claims
- 1073US2026049074A1Thiadiazolyl derivativesIDEAYA BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1169US12503467B22-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2019·Granted Dec 23, 2025·0 cites·17 claims
- 1264US2024108626A1Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitorIDEAYA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1361US2025376467A1Piperazine substituted indazole compounds as inhibitors of pargIDEAYA BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1459US2026015321A1Chemical compounds and uses thereofIDEAYA BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1557US12509454B2Thiadiazolyl derivativesIDEAYA BIOSCIENCES INC·Filed 2020·Granted Dec 30, 2025·0 cites·7 claims
- 1657US2025243188A1Methionine adenosyltranserase 2a inhibitorsIDEAYA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1757US2024287080A1O-linked thiadiazolyl compounds as dna polymerase theta inhibitorsIDEAYA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1854US2024208965A1Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1954US2025325552A1Substituted thiadiazolyl derivatives as dna polymerase theta inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2054US2023227409A1Quinolinone derivatives as methionine adenosyltransferase 2a inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2153US2022389003A14-substituted indole and indazole sulfonamido derivatives as parg inhibitorsIDEAYA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2253US2023257377A12-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2352US2023257359A14-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2451US2022401440A1Dosing regimens for a protein kinase c inhibitorIDEAYA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2551US2024335440A1Combination therapy comprising a pkc inhibitor and a c-met inhibitorIDEAYA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2651US2024207257A1Combination therapy comprising a pkc inhibitor and a mek inhibitorIDEAYA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2750US2023303510A1Cyclized acetamido derivatives as dna polymerase theta inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2849US2026083731A1Methods of treating uveal melanoma with a pkc inhibitorIDEAYA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2949US2022340875A1Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compoundsIDEAYA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3049US2025090533A1Combination therapy comprising a mat2a inhibitor and a taxaneIDEAYA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3148US2021254006A1Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compoundsIDEAYA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3247US2022098154A1Acetamido derivatives as dna polymerase theta inhibitorsIDEAYA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3347US2024269143A1Combination therapy comprising a mat2a inhibitor and type i prmt inhibitorIDEAYA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3445US11548867B2Amido compounds as AhR modulatorsIDEAYA BIOSCIENCES INC·Filed 2018·Granted Jan 10, 2023·0 cites·19 claims
- 3545US11530220B2Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhRIDEAYA BIOSCIENCES INC·Filed 2019·Granted Dec 20, 2022·0 cites·21 claims
- 3644US2022305008A1Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitorsIDEAYA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3744US2021387968A1Heteroarylmethylene derivatives as dna polymerase theta inhibitorsIDEAYA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3844US2025017921A1Pharmaceutical combination and tumor treatmentIDEAYA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3936US2021371855A1Methods of inhibiting proliferative cellsIDEAYA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when IDEAYA BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →